• Clinical Trials

Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020

Tokyo, September 18, 2020: Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative…